Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Auscap Asset Management 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Auscap Asset Management)

Primary Source Intelligence • Q2 2024 Letter Analysis

Auscap Asset Management Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Auscap Asset Management. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+13.4%

Digest Analysis

Quick Take

"Auscap makes a compelling case for active management in Australia, where the index is overweight struggling banks and iron ore miners facing Chinese demand decline."

Executive Summary

Auscap argues that while passive investing has dominated in the US due to strong performance from large technology companies, the conditions in Australia favor active management. The ASX200 is overweight large banks (22% of index) that have failed to grow earnings meaningfully over the past decade and face increasing competition and costs. The index is also heavily exposed to iron ore miners (12.8%) at a time when Chinese steel consumption has peaked and new supply is coming online. In contrast, the Australian economy is well-positioned for strong growth driven by population growth, natural resources demand, proximity to Asia, and sound institutions. The manager sees many mid-cap opportunities with strong competitive advantages and organic growth potential. They highlight ResMed as an example, a dominant sleep apnea device company trading at attractive valuations despite concerns about GLP-1 weight loss drugs. The fund believes concerns about GLP-1 impact are overblown and sees significant runway for ResMed's earnings growth.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The manager demonstrates high conviction through concentrated positioning (39 positions), detailed analysis of specific holdings like ResMed, and strong views on sector outlooks. They explicitly state ResMed became a significant position and provide detailed thesis defense against GLP-1 concerns.

Growth Outlook

75%

BearishBullish

Bullish (75%)

The manager expresses strong optimism about the Australian economy's prospects, citing structural advantages and expecting growth as strong as any developed economy. They see the domestic market presenting great opportunities over time despite concerns about specific large-cap sectors.

Risk Appetite

60%

DefensiveAggressive

Balanced (60%)

The fund is 96% gross long with significant positions in mid-cap names like ResMed. They are actively deploying capital into opportunities they see as attractively priced, showing a constructive risk appetite while maintaining some selectivity.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

The fund maintains 96% gross long exposure with 4% cash, suggesting stable positioning. While they added ResMed as a significant position over the past year, there's no indication of major recent deployment changes or cash level movements.

Forward Guidance

50%

CautiousExpansionary

Neutral (50%)

The manager indicates they will continue to focus on identifying reasonably priced businesses with strong earnings growth potential, particularly in the mid-cap space. They express confidence in their ability to find opportunities but don't signal aggressive near-term deployment.

Language Signal

40%

BearishBullish

Balanced (40%)

The letter balances optimistic language about Australian opportunities and structural advantages with significant discussion of risks facing large index constituents like banks and miners. The tone is constructive but measured.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges specific sector risks including Chinese steel demand decline, banking sector headwinds, and GLP-1 concerns for ResMed. However, these are presented as manageable challenges rather than systemic threats, with detailed analysis provided for each concern.

Opportunity Density

75%

ScarceAbundant

Abundant (75%)

The manager sees abundant opportunities in the Australian mid-cap space, describing many companies with strong competitive advantages and organic growth potential. They contrast this rich opportunity set with the challenges facing large-cap index constituents.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The manager emphasizes long-term investing throughout, describing ResMed as attractive for long-term investors and focusing on companies that will grow earnings over time. They discuss structural economic advantages that should benefit Australia over extended periods.